A radical strategy for Medtronic
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Zimmer ditches slow-growing business to refocus
And the move will shake up the orthopaedic robotics scene.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Medtechs that book the most sales per employee face the greatest losses
Welcome to the calm before the Covid-19 storm.
